News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Clyburn Frank
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/05/2023 |
4
| Clyburn Frank (CEO) has filed a Form 4 on INTERNATIONAL FLAVORS & FRAGRANCES INC|
Txns:
| Granted 35,006 restricted stock units
@ $0 |
|
| 03/02/2023 |
4
| Clyburn Frank (CEO) has filed a Form 4 on INTERNATIONAL FLAVORS & FRAGRANCES INC|
Txns:
| Paid exercise price by delivering 477 shares
@ $91.64, valued at
$43.7k
Exercised 1,323 options to buy
@ $0 |
|
| 05/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/04/2021 |
4
| Clyburn Frank (EVP & Pres ? Human Health) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 39,479 restricted stock units
@ $0 |
|
| 11/02/2021 |
4
| Clyburn Frank (EVP & Pres ? Human Health) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 2,358 shares
@ $88.05, valued at
$207.6k
Paid exercise price by delivering 1,162 shares
@ $88.05, valued at
$102.3k
Sold 39,762 shares
@ $87.8698, valued at
$3.5M
Exercised 2,358 restricted stock units
@ $0
Exercised 19,915 options to buy
@ $0
Exercised 19,847 options to buy
@ $0 |
|
| 05/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2021 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 9,432 shares
@ $72.62, valued at
$685k
|
|
| 11/03/2020 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 2,287 shares
@ $75.89, valued at
$173.6k
Paid exercise price by delivering 1,137 shares
@ $75.89, valued at
$86.3k
Exercised 2,287 restricted stock units
@ $0 |
|
| 08/06/2020 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 18,876 shares
@ $0
Sold 18,876 shares
@ $81.5466, valued at
$1.5M
Exercised 18,876 options to buy
@ $39.29, valued at
$741.6k
|
|
| 05/29/2020 |
4
| Clyburn Frank (Director) has filed a Form 4 on DuPont de Nemours, Inc.|
Txns:
| Granted 3,438 shares
@ $49.46, valued at
$170k
|
|
| 05/06/2020 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 1,904 shares
@ $77.67, valued at
$147.9k
Paid exercise price by delivering 938 shares
@ $77.67, valued at
$72.9k
Exercised 3,752 shares
@ $76.86, valued at
$288.4k
Paid exercise price by delivering 1,848 shares
@ $76.86, valued at
$142k
Exercised 1,904 restricted stock units
@ $0
Exercised 3,752 restricted stock units
@ $0 |
|
| 05/05/2020 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 75,514 options to buy
@ $77.67, valued at
$5.9M
|
|
| 03/03/2020 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 4,905 shares
@ $76.56, valued at
$375.5k
|
|
| 11/01/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/05/2019 |
4
| Clyburn Frank (Director) has filed a Form 4 on DuPont de Nemours, Inc.|
Txns:
| Granted 2,240 shares
@ $76.1, valued at
$170.5k
|
|
| 05/13/2019 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 4,389 shares
@ $0
Paid exercise price by delivering 2,162 shares
@ $78.33, valued at
$169.3k
Exercised 4,389 restricted stock units
@ $78.33, valued at
$343.8k
|
|
| 05/09/2019 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Sold 25,000 shares
@ $77.7273, valued at
$1.9M
Exercised 25,000 options to buy
@ $39.29, valued at
$982.3k
|
|
| 05/07/2019 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Exercised 1,904 shares
@ $0
Paid exercise price by delivering 938 shares
@ $80, valued at
$75k
Granted 50,808 options to buy
@ $80, valued at
$4.1M
Exercised 1,904 restricted stock units
@ $80, valued at
$152.3k
|
|
| 02/27/2019 |
4
| Clyburn Frank (EVP, Chief Commercial Officer) has filed a Form 4 on Merck & Co., Inc.|
Txns:
| Granted 4,017 shares
@ $80.38, valued at
$322.9k
|
|
|
|